ASBP · Aspire Biopharma Holdings, Inc.
$8.87
-0.38 (-4.11%)
At close · Sep 4
View the 10-Q filed Aug 13, 2026
Customer concentration
— top customer 15% of revenue
One customer — 15% of revenue (the six months ended June 30, 2026)
“One customer accounted for approximately 15% of the Company’s total revenues during the six months ended June 30, 2026.”
Market Cap
$12.62M
Shares
1.40M
ASBP metrics
42 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$8.87
Market cap
$12.62M
Price action
19 metricsPrice change (1W)
+4.2%
Price change (30D)
+25.6%
Price change (3M)
+66.1%
Price change (6M)
+664.7%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
3,635.7%
Beta
6.4
RSI (14D)
62.5
Price vs SMA 50
+23.8%
Price vs SMA 200
—
Avg volume (3M)
268,785
Relative volume
0.2
Average dollar volume
$1.44M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
1.40M
Valuation
12 metricsP / E (TTM)
0.0
Trailing earnings · reciprocal yield 5,805.0%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.1
reciprocal yield 93.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-87.5%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
-1.9%
Operating margin
-312,016.9%
Trailing 12 months
Net margin
-394,725.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$7.32M
Net income (TTM)
−$11.05M
Trailing 12 months
Diluted EPS (TTM)
$514.90
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2,424.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-94.0%
Return on assets
-81.6%
Debt / equity
—
Current ratio
8.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
7.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$12.17M
Latest balance sheet
Cash & equivalents
$12.17M
Total assets
$13.54M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$7.19M
Capital expenditures (TTM)
—
R&D (TTM)
$838,139
SG&A (TTM)
—
Stock compensation (TTM)
$157,500
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
38
13F filer change QoQ
-6
Institutional ownership
493.8%
Short interest
3 metricsShort interest
4.7%
Latest settlement · 2.1 days to cover
Days to cover
2.1d
Short-squeeze score
59 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—